| Symbol | ALLO |
|---|---|
| Name | ALLOGENE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 457-2700 |
| Fax | — |
| — | |
| Website | https://www.allogene.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. Additional info from NASDAQ: |
New Form SCHEDULE 13G - Allogene Therapeutics, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001231919-26-000398 <b>Size:</b> 40 KB
Read more📋 Yoshiyama Annie (Officer) plans to sell 10K shares of Allogene Therapeutics, Inc. (at $2.31 each, total $22K) Filed: Apr 21, 2026 | ID: 000001
Read moreAllogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Read moreAllogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
Read moreAllogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Read more(99% Neutral) ALLOGENE THERAPEUTICS, INC. (ALLO) Provides Update on manager for general corporate purposes
Read moreNew Form 424B5 - Allogene Therapeutics, Inc. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001193125-26-157128 <b>Size:</b> 543 KB
Read moreAllogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
Read moreAllogene Therapeutics Announces Pricing of Public Offering of Common Stock
Read more(99% Neutral) ALLOGENE THERAPEUTICS, INC. (ALLO) Announces Business Combination
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07085104 | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allo… | Phase1 | Systemic Lupus Erythematosus (With and Without Nephritis) | Recruiting | 2025-11-13 | 2032-10-01 | ClinicalTrials.gov |
| NCT06925685 | Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product | — | Hematologic Malignancies | Enrolling_By_Invitation | 2025-01-31 | 2039-01-01 | ClinicalTrials.gov |
| NCT06500273 | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase2 | Large B-cell Lymphoma | Recruiting | 2024-06-18 | 2032-12-01 | ClinicalTrials.gov |
| NCT05714345 | Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lym… | Phase2 | Relapsed/Refractory Large B Cell Lymphoma | Terminated | 2023-11-01 | 2024-10-28 | ClinicalTrials.gov |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in P… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2021-06-06 | 2023-10-11 | ClinicalTrials.gov |
| NCT04696731 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear C… | Phase1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Active_Not_Recruiting | 2021-02-24 | 2025-12-01 | ClinicalTrials.gov |
| NCT04416984 | Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults Wit… | Phase1 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Active_Not_Recruiting | 2020-05-21 | 2029-05-01 | ClinicalTrials.gov |
| NCT04093596 | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Re… | Phase1 | Relapsed/Refractory Multiple Myeloma | Active_Not_Recruiting | 2019-09-23 | 2027-09-01 | ClinicalTrials.gov |
| NCT03939026 | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With… | Phase1 | Relapsed/Refractory Large B Cell Lymphoma | Completed | 2019-05-01 | 2025-01-28 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ALLO-329 | GENETIC | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Systemic Lupus Erythematosus (With and Without Nephritis) | RECRUITING | NCT07085104 |